Polaryx Therapeutics, Inc. (PLYX) News
Follow Polaryx Therapeutics, Inc. (PLYX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Polaryx Therapeutics names Will Charlton chief medical officer
Polaryx Therapeutics appointed Will Charlton, M.D., M.A.S. as chief medical officer to lead clinical execution for PLX-200 and the SOTERIA Phase 2 trial.
REGULATION | Sep 01, 2026, 08:44 PM UTC
L
Polaryx Therapeutics appoints Dr. Will Charlton as Chief Medical Officer
Polaryx Therapeutics appointed Dr. Will Charlton as Chief Medical Officer.
EQUITY | Sep 01, 2026, 12:31 PM UTC
L
Polaryx Therapeutics advances operational readiness for SOTERIA Phase 2 basket trial
Polaryx Therapeutics (PLYX) says it is advancing operational readiness for its SOTERIA Phase 2 basket trial.
EQUITY | Aug 25, 2026, 12:30 PM UTC
L
Analysts initiate coverage on ACHV, ALGM, KZIA, MTSI, PLYX, SBSW
Several brokers initiate or reiterate bullish coverage on ACHV, ALGM, KZIA, MTSI, PLYX and SBSW, including overweight, buy and strong buy ratings.
EQUITY | Aug 13, 2026, 10:50 AM UTC